Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM8Y2N
|
|||
| Drug Name |
DZD9008
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 1/2 | [1] | |
| Company |
Dizal Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | EGFR Exon20ins mutant (EGFR Exon20ins) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03974022) Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Dizal Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.